Source: nfl.com | Re-Post Duerson Fund 3/29/2017 –
NFL Commissioner Roger Goodell has named Dr. Allen Sills as the NFL’s Chief Medical Officer (CMO), a new full-time position based in New York.
Dr. Sills joins the NFL from Vanderbilt University Medical Center where he serves as Professor of Neurological Surgery, Orthopaedic Surgery and Rehabilitation, and Founder and Co-Director of the Vanderbilt Sports Concussion Center.
Dr. Sills, a neurosurgeon who has specialized in the treatment of athletes, will strengthen the NFL’s ongoing efforts to advance the health and safety of the sport. He will work closely with team medical staffs across the league, the NFL Players Association and its advisors and the many medical and scientific experts who comprise the NFL’s medical committees and guide the NFL’s health and research efforts.
“There is no higher priority for the NFL than player health and safety and we continually seek to raise our standards and then surpass them,” said Commissioner Goodell. “We sought a highly-credentialed physician and leader with experience as a clinician and researcher, and Dr. Sills’ extensive experience caring for athletes makes him the right choice for this important position.”
“We conducted an intensive international search which included many leading experts in sports medicine,” said Dr. John York, Co-chairman, San Francisco 49ers and Chairman of the NFL Owners’ Health and Safety Advisory Committee. “Dr. Sills stood out among the highly credentialed and qualified applicants.”
The appointment follows a rigorous search conducted by a premier panel of health and medical experts led by Dr. Betsy Nabel, Chief Health and Medical Advisor to the NFL and President of Brigham Health, and including Dr. Rob Heyer, President of the NFL Physicians Society and Team Internist for the Carolina Panthers,Ronnie Barnes, Senior Vice President, Medical Services and Head Athletic Trainer for the New York Giants, Dr. Robert Cantu, Clinical Professor of Neurosurgery and Co-Director, Center for the Study of Traumatic Encephalopathy, Boston University School of Medicine, and Peter Foss, GE Healthcare.